drugset / Trial / NCT01286467
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.
Timeline
- Start
- 2011-05-11
- Primary completion
- 2012-05-10
- Completion
- 2012-12-28
Publications
- Fostvedt LK, Shaik N, Martinelli G, Wagner AJ, Ruiz-Garcia A. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. Expert Rev Clin Pharmacol. 2021 Jul;14(7):927-935. doi: 10.1080/17512433.2021.1925538. Epub 2021 May 18.
- Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry AB. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 1;21(5):1044-51. doi: 10.1158/1078-0432.CCR-14-1116. Epub 2014 Nov 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glasdegib | Small molecule | 80 mg | Oral |
| Subject | Glasdegib | Small molecule | 320 mg | Oral |
| Subject | Glasdegib | Small molecule | 640 mg | Oral |